Home » Topics » BioWorld Science, Patents

BioWorld Science, Patents
RSS

Fibrinogen receptor antagonists under development at E. Merck

Jan. 10, 1997

Merck & Co. describes avermectin analogue

Jan. 10, 1997

Thrombin-binding anticoagulant disclosed by Japanese scientists

Jan. 10, 1997

Novel antitumor/immunomodulatory agents isolated by Japanese investigators

Jan. 9, 1997

Potential HIV-1 therapy disclosed by Houghten

Jan. 9, 1997

KGF receptor antagonists developed by U.S. researchers

Jan. 9, 1997

High-affinity inhibitor of biogenic amine transporters described

Jan. 9, 1997

Pharmacia & Upjohn describes selective 5-HT2 antagonists

Jan. 9, 1997

Galderma develops novel compounds active on cell differentiation and proliferation

Jan. 9, 1997

Hoechst Japan describes immunosuppressive peptides

Jan. 8, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...
IMV-101 shows promise for B-cell malignancies
BioWorld Science
IMV-101 is a new CAR T-cell therapy targeting CD19 developed by Suzhou Immunofoco Biotechnology Co. Ltd. for the potential treatment of B-cell malignancies and...